Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Symbol: ZURA) is a clinical-stage biotechnology company dedicated to advancing medical science by developing novel treatments for immune and inflammatory disorders. The company's leading asset, ZB-168, is an anti-IL7Rα inhibitor with promising applications in conditions like alopecia areata and other inflammatory diseases. ZB-168 targets the IL7 and TSLP biological pathways, which are key drivers in these conditions, aiming to provide a new therapeutic option where few exist.
Zura Bio is committed to building a robust portfolio of therapeutic indications for ZB-168. The company is actively focused on demonstrating the drug’s efficacy, safety, dosing convenience, and mechanism of action, starting with alopecia areata. This effort is supported by Phase 1b data in type 1 diabetes, which has shown a favorable safety profile and strong biological rationale.
Headquartered in London, UK, Zura Bio operates with a global team of experts based in both the UK and the USA. The company leverages cutting-edge research and development to tackle some of the most challenging health issues today.
As a multi-asset company, Zura Bio is well-positioned to make significant contributions to the field of biotechnology. Through strategic partnerships and a commitment to innovation, the company aims to bring life-changing therapies to patients who need them the most.
- Core Business: Biotechnological research and development focused on immune and inflammatory disorders.
- Leading Product: ZB-168, an anti-IL7Rα inhibitor for alopecia areata and other inflammatory diseases.
- Headquarters: London, UK.
- Global Presence: Team members located in the UK and USA.
Zura Bio Limited (Nasdaq: ZURA) has licensed tibulizumab, an anti-IL-17 and anti-BAFF dual antagonist, from Eli Lilly. The compound will be designated as ZB-106 and has already undergone two Phase 1b studies demonstrating an acceptable safety profile. Zura plans to initiate a Phase 2 study for ZB-106 in Systemic Sclerosis in 2024. Additionally, the company has announced a private placement financing to raise approximately $80 million, selling around 18.8 million Class A ordinary shares and pre-funded warrants. The financing is expected to enhance Zura’s cash reserves to approximately $120 million, sufficient to fund operations through 2026. The offering is led by multiple investment firms, and shares are priced at $4.25.
Zura Bio Limited (Nasdaq: ZURA) has appointed Michael D. Howell, Ph.D., as the new Chief Scientific Officer and Head of Translational Science. With over two decades of experience, Dr. Howell will spearhead the scientific strategy and translational research efforts at Zura Bio. Prior to this role, he was a scientific advisor during the company's formation in 2022. His extensive background includes leadership positions at DermTech, Incyte Corporation, and AstraZeneca. Zura Bio focuses on developing therapies for immune and inflammatory disorders and is advancing its pipeline, including Phase 2 programs like ZB-168 and torudokimab. CEO Someit Sidhu expressed confidence in Dr. Howell's expertise to drive the company’s science and clinical development forward.
FAQ
What is the current stock price of Zura Bio (ZURA)?
What is the market cap of Zura Bio (ZURA)?
What does Zura Bio Limited do?
What is Zura Bio's leading product?
What is ZB-168?
Where is Zura Bio headquartered?
Does Zura Bio have a global presence?
What are the current projects of Zura Bio?
Who are Zura Bio's target patients?
What is the significance of the Phase 1b data for ZB-168?
What is the strategic focus of Zura Bio?
How does Zura Bio contribute to biotechnology?
